Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase

被引：29

作者：

Budillon, A ^{[1
]}

Bruzzese, F ^{[1
]}

Di Gennaro, E ^{[1
]}

Caraglia, M ^{[1
]}

机构：

[1] Natl Canc Inst, Dept Expt Oncol, Expt Pharmacol Unit, Fondaz G Pascale, I-80131 Naples, Italy

来源：

CURRENT DRUG TARGETS | 2005年 / 6卷 / 03期

关键词：

multi-targets drugs; heat shock protein 90; heat shock protein 90 inhibitors; histone deacetylase; histone deacetylase inhibitors; epigenetics; multi-chaperone; ErbB;

D O I：

10.2174/1389450053765905

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In spite of the improvement of conventional medical therapy for cancer treatment, the impact on cancer related mortality in the last tell years has been modest especially for advanced disease in adults. On the other hand, understanding of molecular events underlining tumor development lead to the definition of new molecular targets for novel anti-tumor therapeutical approaches. Oil this regard, several biotechnology products selected by academic as well as industrial research are currently in clinical trials. Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anticancer therapy. In addition, the heterogeneity Of tumor cells within a selected neoplastic lesions as well as the redundancy of proliferative and survival pathways present in cancer cells favor the development of single drugs that are able to affect multiple pathways. Inhibitors of heat shock protein 90 and of histone deacetylase are two novel classes of multi-target agents that entered recently in clinical studies.

引用

页码：337 / 351

页数：15

共 159 条

[1]

An WG, 2000, CELL GROWTH DIFFER, V11, P355

[2] Regulation of p53 stability [J].